Earnings Recaps

Browse reported earnings of the most popular stocks

Nov 13, 2026 Nov 12, 2026 Nov 11, 2026 Nov 10, 2026 Nov 9, 2026 Nov 8, 2026 Nov 7, 2026 Nov 6, 2026 Nov 5, 2026 Nov 4, 2026 Nov 3, 2026 Nov 2, 2026 Nov 1, 2026 Oct 31, 2026 Oct 30, 2026 Oct 29, 2026 Oct 28, 2026 Oct 27, 2026 Oct 26, 2026 Oct 25, 2026 Oct 24, 2026 Oct 23, 2026 Oct 22, 2026 Oct 21, 2026 Oct 20, 2026 Oct 19, 2026 Oct 18, 2026 Oct 17, 2026 Oct 16, 2026 Oct 15, 2026 Oct 14, 2026 Oct 13, 2026 Oct 11, 2026 Oct 10, 2026 Oct 9, 2026 Oct 8, 2026 Oct 7, 2026 Oct 3, 2026 Oct 2, 2026 Oct 1, 2026 Sep 30, 2026 Sep 29, 2026 Sep 27, 2026 Sep 26, 2026 Sep 25, 2026 Sep 24, 2026 Sep 23, 2026 Sep 19, 2026 Sep 18, 2026 Sep 17, 2026 Sep 16, 2026 Sep 14, 2026 Sep 13, 2026 Sep 12, 2026 Sep 11, 2026 Sep 10, 2026 Sep 9, 2026 Sep 8, 2026 Sep 5, 2026 Sep 4, 2026 Sep 3, 2026 Sep 2, 2026 Sep 1, 2026 Aug 31, 2026 Aug 30, 2026 Aug 29, 2026 Aug 28, 2026 Aug 27, 2026 Aug 26, 2026 Aug 25, 2026 Aug 23, 2026 Aug 22, 2026 Aug 21, 2026 Aug 20, 2026 Aug 19, 2026 Aug 18, 2026 Aug 17, 2026 Aug 16, 2026 Aug 15, 2026 Aug 14, 2026 Aug 13, 2026 Aug 12, 2026 Aug 11, 2026 Aug 10, 2026 Aug 9, 2026 Aug 8, 2026 Aug 7, 2026 Aug 6, 2026 Aug 5, 2026 Aug 4, 2026 Aug 3, 2026 Aug 2, 2026 Aug 1, 2026 Jul 31, 2026 Jul 30, 2026 Jul 29, 2026 Jul 28, 2026 Jul 27, 2026 Jul 26, 2026 Jul 25, 2026 Jul 24, 2026 Jul 23, 2026 Jul 22, 2026 Jul 21, 2026 Jul 20, 2026 Jul 19, 2026 Jul 18, 2026 Jul 17, 2026 Jul 16, 2026 Jul 12, 2026 Jul 11, 2026 Jul 10, 2026 Jul 9, 2026 Jul 3, 2026 Jul 2, 2026 Jul 1, 2026 Jun 30, 2026 Jun 28, 2026 Jun 27, 2026 Jun 26, 2026 Jun 25, 2026 Jun 24, 2026 Jun 20, 2026 Jun 19, 2026 Jun 18, 2026 Jun 17, 2026 Jun 15, 2026 Jun 14, 2026 Jun 13, 2026 Jun 12, 2026 Jun 11, 2026 Jun 10, 2026 Jun 9, 2026 Jun 6, 2026 Jun 5, 2026 Jun 4, 2026 Jun 3, 2026 Jun 2, 2026 Jun 1, 2026 May 31, 2026 May 30, 2026 May 29, 2026 May 28, 2026 May 27, 2026 May 26, 2026 May 24, 2026 May 23, 2026 May 22, 2026 May 21, 2026 May 20, 2026 May 19, 2026 May 18, 2026 May 17, 2026 May 16, 2026 May 15, 2026 May 14, 2026 May 13, 2026 May 12, 2026 May 11, 2026 May 10, 2026 May 9, 2026 May 8, 2026 May 7, 2026 May 6, 2026 May 5, 2026 May 4, 2026 May 3, 2026 May 2, 2026 May 1, 2026 Apr 30, 2026 Apr 29, 2026 Apr 23, 2026 Apr 22, 2026 Apr 21, 2026 Apr 20, 2026 Apr 18, 2026 Apr 17, 2026 Apr 16, 2026 Apr 15, 2026 Apr 14, 2026 Apr 13, 2026 Apr 10, 2026 Apr 9, 2026 Apr 8, 2026 Apr 7, 2026 Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026
79 companies Today

American International Group, Inc.

AIG Q3 2026
Reported: 2026-11-05

AIG posted quarterly adjusted EPS of $2.60 and 8% net premiums written growth, while the stock rose 1.5%—a modestly positive reaction. Performance was mixed across the portfolio: management cited intensifying competition in North American E&S property and casualty and pressure on energy pricing, while reporting growth in international commercial and personal insurance.

Key takeaways
  • Adjusted after-tax income was $1.1 billion; core operating ROE was 11.1%.
  • Underwriting income was $564 million. The accident-year combined ratio excluding catastrophes was 88.4%, versus a 91.3% calendar-year combined ratio.
  • Net premiums written increased 8% year over year, or 10% excluding North America property. International commercial grew 13% and global personal grew 9%; North America commercial grew 2%, or 6% excluding property.
  • Management said competition has intensified in Lexington, particularly in property and increasingly in casualty, and is reducing exposure in large accounts. In energy, elevated losses and inflation are driving costs higher even as new capacity pushes market rates lower.
  • AIG returned $787 million to shareholders in the quarter, including $527 million in share repurchases and $260 million in dividends.

Advanced Micro Devices, Inc.

AMD Q3 2026
Reported: 2026-11-05

AMD’s shares rose 1.0% after the earnings release, a relatively muted reaction to record revenue and rapid data center growth. The results were positive, but the market move does not signal a clear breakout response.

Key takeaways
  • Revenue increased 45% year over year to $13.4 billion; non-GAAP EPS rose 74% to $2.09.
  • Data center revenue nearly doubled, up 97% to a record $8.5 billion, or 64% of total revenue. Server sales to both cloud and enterprise customers more than doubled.
  • AMD said it significantly exceeded its prior outlook for server growth of more than 80%; it expects data center growth acceleration to continue in Q4.
  • Helios production ramped as planned, with MI455X shipping in volume and initial customer racks online. AMD expects Helios deployments to increase substantially in Q4 as production scales and OEM systems begin shipping.
  • Venice shipments began in Q3, with first OEM systems expected this quarter. Partners have committed more than 240 platforms, 20% more than for Turin, while cloud deployments are underway ahead of planned early-2027 instance rollouts.

Amgen Inc.

AMGN Q3 2026
Reported: 2026-11-05

Amgen’s shares rose 3.7% after the company reported 8% revenue growth and 27% growth from its six key growth drivers. Repatha, EVENITY and TEZSPIRE led the commercial performance, while the transcript excerpt does not provide updated financial guidance.

Key takeaways
  • Third-quarter revenue grew 8% year over year to $10.4 billion; product sales also grew 8%.
  • The six key growth drivers grew 27% and accounted for more than 70% of product sales. Seventeen products delivered double-digit sales growth, and 17 were annualizing above $1 billion based on third-quarter sales.
  • Repatha sales rose 37% to $1.1 billion; EVENITY sales rose 39% to $751 million; TEZSPIRE sales rose 43% to $538 million.
  • Amgen generated $3.7 billion in free cash flow, increased R&D investment 11% year over year and spent another $600 million on capital expenditures.
  • The company reported positive Phase III results for IMDELLTRA, TEZSPIRE in eosinophilic esophagitis and dazodalibep. The excerpt gives no detailed results or updated guidance.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...